BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Top Cited Papers
Open Access
- 4 October 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 120 (14), 2843-2852
- https://doi.org/10.1182/blood-2012-02-413021
Abstract
We investigated the therapeutic potential of JQ1, an inhibitor of the BET class of human bromodomain proteins, in B-cell acute lymphoblastic leukemiaKeywords
This publication has 56 references indexed in Scilit:
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaNature, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Ribosome biogenesis factors bind a nuclear envelope SUN domain protein to cluster yeast telomeresThe EMBO Journal, 2011
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Epigenetic modifications as therapeutic targetsNature Biotechnology, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemiaNature Genetics, 2009
- New insights into the regulation of T cells by γc family cytokinesNature Reviews Immunology, 2009
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005